Skip to main content
. 2014 Aug 6;2014(8):CD003459. doi: 10.1002/14651858.CD003459.pub4

Comparison 4. Methotrexate and Infliximab versus Infliximab.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Failure to enter remission at 14 weeks or 24 weeks 2   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
2 Adverse events 1   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
3 Serious adverse events 1   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
4 Withdrawals due to adverse event 2   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
HHS Vulnerability Disclosure